We are interested in pharmacological targeting of oncogenes and growth factors relevant for malignant disease using mouse and tissue culture model systems.
- Development of novel gene targeting strategies based on RNAi/siRNAs, ribozymes
- Polyethylenimine (PEI)-based nanoparticles for the therapeutic in vivo delivery of small RNA molecules
- Functional analysis of various growth factors and receptors, relevant in tumor growth and tumor angiogenesis
(e.g., HER-1/EGFR, HER-2/erbB2, FGF-BP, PTN, ALK, Pim-1)
- Development of novel treatment strategies based on the specific knockdown of pathologically relevant genes
- A sensitive polymerase chain reaction-based method for detection and
quantification of metastasis in human xenograft mouse models.
Malek A, Catapano CV, Czubayko F, Aigner A.
Clin Exp Metastasis. (2010) 27:261-71.
- RNAi-mediated gene-targeting through systemic application of
polyethylenimine (PEI)-complexed siRNA in vivo.
Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A.
Gene Ther. (2005) 12:461-6.
- Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation
of prostate cancer cells in vitro and in vivo.
Aigner A, Renneberg H, Bojunga J, Apel J, Nelson PS, Czubayko F.
Oncogene. (2002) 21:5733-42.
- A secreted FGF-binding protein can serve as the angiogenic switch in human cancer.
Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A.